Table 2.

Next-generation ALK TKIs in clinical development

DrugCompanyClinical development
Alectinib (CH5424802/RO5424802)Roche/GenentechFDA approved
Ceritinib (LDK378)NovartisFDA approved
Brigatinib (AP26113)ARIADPhase II/III
Lorlatinib (PF-06463922)PfizerPhase I/II
Entrectinib (RXDX-101)IgnytaPhase II
TSR-011TesaroPhase I/II
X-396XcoveryPhase I/II
CEP-37440TevaPhase I